Notably, natalizumab therapy could enhance the expression of molecules with tolerogenic function including HLA-G, HLA-DR, PD-L1 and that of molecules with migratory function such as CCR7 on pDCs in patients with MS [120]. The gene discussed is CCR7; the disease is myeloid sarcoma.